Coca-Cola Europacific Partners (CCEP) Stock Price & How to Invest

Coca-Cola Europacific Partners makes, packages, sells and delivers non-alcoholic ready-to-drink beverages under licence from The Coca-Cola Company and a handful of partner brand owners. Its portfolio spans Coca-Cola, Coca-Cola Zero Sugar, Fanta, Sprite, Schweppes, Monster Energy, Costa Coffee ready-to-drink, Powerade, Capri-Sun, Vitaminwater, Smartwater and, in Australia and the Pacific, the former Amatil brands. The territory list runs across Western Europe (Great Britain, Germany, Spain, France, Belgium, the Netherlands, Portugal, Norway, Sweden, Iceland and smaller markets) plus an Asia Pacific segment built from the 2021 acquisition of Coca-Cola Amatil, which brought Australia, New Zealand, Indonesia, Papua New Guinea and Fiji, and the 2024 purchase of a 60% stake in Coca-Cola Beverages Philippines alongside Aboitiz Equity Ventures. Around ~39,000 employees run the plants, warehouses and route-to-market fleets that reach several hundred million consumers. Ownership is concentrated: Olive Partners, tied to the Daurella family, holds roughly ~36%, and The Coca-Cola Company itself holds roughly ~17%.

The investment picture is a franchised, capital-intensive staples business with better arithmetic than most bottlers get credit for. Trailing revenue of ~EUR 21.4bn converts at roughly ~$24.4bn, operating margin sits near ~13.5%, return on equity near ~23.5%, and free cash flow ran about ~$2.6bn over the trailing year. First-half 2026 revenue of ~EUR 10.7bn grew ~4.4% as reported and ~6.1% currency-neutral, with operating profit of ~EUR 1.48bn up ~8.1% currency-neutral, and management reaffirmed full-year guidance of ~3% to 4% revenue growth, roughly ~7% operating profit growth and comparable free cash flow of at least ~EUR 1.7bn. Capital returns are explicit: an interim dividend of ~EUR 0.82 per share, a payout policy around ~50% of comparable earnings, and a ~EUR 1bn buyback that was about ~EUR 593m complete by the end of July 2026. Against that, the stock trades near ~20.9x trailing and ~19.5x forward earnings with ~13.9bn of gross debt, a persistent valuation gap to KO that reflects exactly what a bottler is: the party carrying the trucks, the plants and the packaging regulation.

Currency is the first thing a US shareholder should understand: CCEP reports in euros while the Nasdaq line quotes in dollars, so a weaker euro compresses reported dollar returns even when the underlying business is fine, and the group also carries Australian dollar, sterling, rupiah and peso translation exposure. Leverage is real, with roughly ~$13.9bn of gross debt against ~$2.3bn of cash and a current ratio near ~0.89, a legacy of financing the Amatil and Philippines acquisitions. Regulation is a standing headwind rather than an event: sugar levies across the UK, Ireland, Spain, Portugal and elsewhere, extended producer responsibility fees on packaging, deposit return schemes and the EU Packaging and Packaging Waste Regulation all raise the cost of putting a drink on a shelf. The whole business also depends on bottling and distribution agreements with The Coca-Cola Company, which owns roughly ~17% of CCEP and sets concentrate pricing, so the economics are negotiated rather than sovereign. Product-quality events can be expensive and public, as in January 2025 when CCEP recalled Coca-Cola and related products produced at its Ghent plant across Belgium, the Netherlands, Luxembourg, France, Germany and Great Britain after elevated chlorate levels were detected. As of August 2026 no active US securities-fraud class action against CCEP was identified, and the company filed its FY2025 Form 20-F in March 2026 with continuing routine 6-K filings, with no Form 25 or delisting process in evidence.

11 analysts publish price targets on CCEP, averaging $112.36 against a $106.03 price as of August 2026, or +6.0%. The published targets run from $100.25 to $120.42, a narrow spread, and the ratings split 8 buy, 4 hold, 0 sell. Over the last six months there have been 7 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full CCEP forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Coca-Cola Europacific Partners. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Asia Pacific scale, with the Philippines as the swing factor. Australia, New Zealand, Indonesia, Papua New Guinea, Fiji and now the Philippines give CCEP a growth engine that a purely European bottler would lack. The most optimistic published target, $120.42, assumes this works close to its best case.

The case against. Currency is the first thing a US shareholder should understand: CCEP reports in euros while the Nasdaq line quotes in dollars, so a weaker euro compresses reported dollar returns even when the underlying business is fine, and the group also carries Australian dollar, sterling, rupiah and peso translation exposure. The most pessimistic target, $100.25, is roughly what CCEP is worth if this bites instead.

Read the full bull and bear case on CCEP, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Coca-Cola Europacific Partners's investor relations page or your broker.

• Revenue (TTM): ~EUR 21.4bn (about ~$24.4bn)
• Operating profit / margin (TTM): ~EUR 2.9bn, margin ~13.5%
• Net income / diluted EPS (TTM): ~EUR 2.0bn, ~EUR 4.44 per share
• Market cap / enterprise value: ~$47.5bn / ~$59.9bn
• P/E trailing / forward, EV/EBITDA: ~20.9x / ~19.5x, ~13.7x
• Dividend yield / payout, free cash flow: ~2.3% at ~47% payout, FCF ~$2.6bn

Reported figures are in euros and the conversion to dollars moves with the exchange rate, so a headline US revenue number of ~$24.4bn against a euro base of ~EUR 21.4bn is an artifact of translation rather than of trading. Roughly ~20.9x trailing earnings is a persistent discount to The Coca-Cola Company, which is the market pricing the structural difference between owning a brand and owning the trucks and plants that carry it. Beta near ~0.48 and a payout ratio under half of earnings are what give the shares their defensive character.

Other names that sit close to CCEP: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get CCEP exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so CCEP sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where CCEP fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

CCEP is a low-beta, cash-generative bottler with a franchise moat and real regional growth, priced at a modest discount to the brand owner it depends on, and its results reach a US shareholder through a euro reporting currency.

Whether CCEP is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CCEP a buy or a sell?, and where the stock could go from here in the CCEP stock forecast.

For income investors, whether CCEP pays a dividend and how the payout looks is covered in does CCEP pay a dividend? And to weigh CCEP against a peer, read the full side-by-side comparisons: CCEP vs KO and CCEP vs COKE.